leadf
logo-loader
viewSynairgen PLC

BetterLife surges on UK biotech trial results of interferon inhalation treatment for coronavirus

BetterLife Pharma Inc (OTCQB:BETRF) (CSE:BETR) CEO Ahmad Doroudian tells Proactive its encouraged by positive results from a clinical trial by a UK biotech, which suggested that an interferon inhalation treatment for coronavirus reduces the need for intensive care.

Doroudian says data from the Synairgen PLC (LON:SNG) trial showed that people who received SNG001, an inhaled formulation of interferon beta, had a 79% lower risk of developing severe coronavirus disease compared to those given the placebo.

Quick facts: Synairgen PLC

Price: 177 GBX

AIM:SNG
Market: AIM
Market Cap: £292.21 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Synairgen PLC named herein, including the promotion by the Company of Synairgen PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Mandalay Resources latest drilling shows impressive results from Youle...

Mandalay Resources (TSE: MND-OTCQB: MNDJF) President and CEO Dominic Duffy joined Steve Darling from Proactive with news the company has seen some very strong numbers from the latest drill results on the Youle Deposit at their Costerfield Project. Duffy telling Proactive the numbers returned...

1 day, 10 hours ago

2 min read